{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T18:20:27Z","timestamp":1777141227545,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The significance of very early chimerism assessment before day +\u200928, which is considered the moment of engraftment, is still unclear. In this retrospective study, we evaluated the clinical impact of very early chimerism on the clinical outcome after allogeneic haematopoietic stem cell transplantation (allo-HSCT) in children with acute lymphoblastic leukaemia (ALL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study group included 38 boys and 18 girls. Very early chimerism was evaluated on days +\u20097, +\u200914, +\u200921 and\u2009+\u200928 after the transplant. Short tandem repeat polymerase chain reaction (STR PCR) was used to analyse chimerism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall survival (OS) and event-free survival (EFS) were 84 and 80%, respectively. The OS in the group of 24 patients with complete donor chimerism on day +\u200914 was 83%, and it did not differ statistically compared to the 32 patients with mixed chimerism on day +\u200914 (OS was 84%). In our cohort of patients, the matched unrelated donor, male gender of donor, number of transplanted cells above 4.47\u2009\u00d7\u200910\n                      <jats:sup>6<\/jats:sup>\n                      \u2009kg and no serotherapy with anti-thymocyte globulin (ATG) were statistically related to a higher level of donor chimerism. The immunophenotypes of disease, age of patient at time HSCT, recipient sex, stem cell source (peripheral blood\/bone marrow) and conditioning regimen had no impact on early chimerism. Acute graft versus host disease grades II-IV was diagnosed in 23 patients who presented with donor chimerism levels above 60% on day 7.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The data presented in this study provide valuable insight into the analysis of very early chimerism in children with ALL treated with HSCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-019-6360-3","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T03:03:02Z","timestamp":1574737382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of early chimerism status on clinical outcome in children with acute lymphoblastic leukaemia after haematopoietic stem cell transplantation"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-7996","authenticated-orcid":false,"given":"Agnieszka","family":"Zaucha-Pra\u017cmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Mroczkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-9874","authenticated-orcid":false,"given":"Dominik","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-0845","authenticated-orcid":false,"given":"Jerzy R.","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-9129","authenticated-orcid":false,"given":"Katarzyna","family":"Drabko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"6360_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","volume":"366","author":"M Schrappe","year":"2012","unstructured":"Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366:1371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa1110169.","journal-title":"N Engl J Med"},{"issue":"3","key":"6360_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.transci.2018.05.012","volume":"57","author":"Jacek Wachowiak","year":"2018","unstructured":"Wachowiak J, Chybicka A, Kowalczyk JR, Wysocki M, Go\u017adzik J, Gorczy\u0144ska E, Ka\u0142wak K, Styczy\u0144ski J, Drabko K, Pieczonka A. Development and current use of in hematopoietic stem cell transplantation in children and adolescents in Poland: Report of the Polish pediatric study group for hematopoietic stem cell transplantation of the Polish society for pediatric oncology and hematology. Transfus Apher Sci. 2018. https:\/\/doi.org\/10.1016\/j.transci.2018.05.012.","journal-title":"Transfusion and Apheresis Science"},{"key":"6360_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3904\/kjim.2015.089","volume":"33","author":"PH Sung","year":"2018","unstructured":"Sung PH, Im C, Hyun SY, Shim KY, Ji L, Kong JH. Unusual isolated extramedullary relapse of acute lymphoblastic leukemia in the breast despite complete donor hematopoietic chimerism after allogeneic hematopoietic stem cell transplantation. Korean J Intern Med. 2018;33:218\u201320. https:\/\/doi.org\/10.3904\/kjim.2015.089.","journal-title":"Korean J Intern Med"},{"key":"6360_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bmt.1704715","volume":"35","author":"P Bader","year":"2005","unstructured":"Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should we monitor chimerism after allogenic stem cell transplantation? Bone Marrow Transplant. 2005;35:107\u201319. https:\/\/doi.org\/10.1038\/sj.bmt.1704715.","journal-title":"Bone Marrow Transplant"},{"key":"6360_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/leu.2011.244","volume":"26","author":"S Breuer","year":"2012","unstructured":"Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2012;26:509\u201319. https:\/\/doi.org\/10.1038\/leu.2011.244.","journal-title":"Leukemia"},{"key":"6360_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.exphem.2015.02.006","volume":"43","author":"T Stahl","year":"2015","unstructured":"Stahl T, B\u00f6hme MU, Kr\u00f6ger N, Fehse B. Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. Exp Hematol. 2015;43:462\u20138. https:\/\/doi.org\/10.1016\/j.exphem.2015.02.006.","journal-title":"Exp Hematol"},{"key":"6360_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00277-019-03626-w","volume":"98","author":"WC Chia","year":"2019","unstructured":"Chia WC, Khoo TS, Wahid SFSA, Razak NFA, Alauddin H, Sabudin RZAR, Othman A, Hassan R, Hussin NH. Multiplex PCR panel for assessment of chimerism following hematopoietic stem cell transplantation (HSCT). Ann Hematol. 2019;98:1279\u201391. https:\/\/doi.org\/10.1007\/s00277-019-03626-w.","journal-title":"Ann Hematol"},{"key":"6360_CR8","first-page":"281","volume-title":"The EBMT Handbook","author":"T Lion","year":"2012","unstructured":"Lion T. Molecular monitoring after HSCT. Chimerism. In: Apperley J, Carreras E, Gluckman E, Masszi T, editors. The EBMT Handbook, vol. 16.2; 2012. p. 281\u20137. https:\/\/ebmtonline.forumservice.net\/media\/16_2\/tex\/content_alt\/EBMT_Handbook2012_CHAP16_2.pdf."},{"key":"6360_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-3-030-02278-5_20","volume-title":"The EBMT Handbook","author":"Peter Bader","year":"2019","unstructured":"Bader P. Documentation of Engraftment and Chimerism After HSCT. In: Carreras E, Dufour C, Mohty M, Kr\u00f6ger N, editors. The EBMT Handbook Springer, vol. 72. Cham; 2019. p. 539\u201345. https:\/\/doi.org\/10.1007\/978-3-030-02278-5_20."},{"key":"6360_CR10","first-page":"128","volume-title":"Haematopoietic stem cell transplantation","author":"J Apperley","year":"2008","unstructured":"Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T. Principles of conditioning. In: Apperley J, Carreras E, Gluckman E, Masszi T, editors. Haematopoietic stem cell transplantation. Genoa: Forum Service Editore; 2008. p. 128\u201344."},{"key":"6360_CR11","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.transproceed.2017.04.013","volume":"49","author":"M Lejman","year":"2017","unstructured":"Lejman M, Drabko K, Styka B, Winnicka D, Babicz M, Jaszczuk I, Kowalczyk JR. Usefulness of post-transplant hematopoietic chimera monitoring by use of the quantitative fluorescence polymerase chain reaction method. Transplant Proc. 2017. PMID: 28923646;49:1903\u201310. https:\/\/doi.org\/10.1016\/j.transproceed.2017.04.013.","journal-title":"Transplant Proc"},{"key":"6360_CR12","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/leu.2012.66","volume":"26","author":"T Lion","year":"2012","unstructured":"Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, de Weger R, et al. The EuroChimerism concept for a standardized approach to chimeras analysis after allogeneic stem cell transplantation. Leukemia. 2012;26:1821\u20138. https:\/\/doi.org\/10.1038\/leu.2012.66.","journal-title":"Leukemia"},{"key":"6360_CR13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","volume":"22","author":"P Bader","year":"2004","unstructured":"Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P, et al. Increasing mixed Chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic Leucemia after allogeneic stem cell transplantation: possible role for pre-Emptive immunotherapy? J Clin Oncol. 2004;22:1696\u2013706.","journal-title":"J Clin Oncol"},{"key":"6360_CR14","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/bmt.2014.158","volume":"49","author":"XY Qin","year":"2014","unstructured":"Qin XY, Li GX, Qin YZ, Wang Y, Wang FR, Liu DH, et al. Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2014;49:1269\u201377. https:\/\/doi.org\/10.1038\/bmt.2014.158.","journal-title":"Bone Marrow Transplant"},{"key":"6360_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/bjh.13073","volume":"168","author":"JR Clark","year":"2015","unstructured":"Clark JR, Scott SD, Jack AL, Lee H, Mason J, Carter GI, et al. Monitoring of chimeras following allogeneic haematopoietic stem cell transplantation (HSCT): technical recommendations for the use of short tandem repeat (STR) based techniques, on behalf of the United Kingdom National External Quality Assessment Service for leucocyte Immunophenotyping Chimerism working group. Br J Haematol. 2015;168:26\u201337. https:\/\/doi.org\/10.1111\/bjh.13073.","journal-title":"Br J Haematol"},{"key":"6360_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.bmt.1701119","volume":"21","author":"P Bader","year":"1998","unstructured":"Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant. 1998;21:487\u201395. https:\/\/doi.org\/10.1038\/sj.bmt.1701119.","journal-title":"Bone Marrow Transplant"},{"key":"6360_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3324\/haematol.2015.135137","volume":"101","author":"S Preuner","year":"2016","unstructured":"Preuner S, Peters C, P\u00f6tschger U, Daxberger H, Fritsch G, Gryeregger R, et al. Risk assessment of relapse by lineage-specific monitoring of chimerism in children undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia. Haematologica. 2016;101:741\u20136. https:\/\/doi.org\/10.3324\/haematol.2015.135137.","journal-title":"Haematologica"},{"key":"6360_CR18","first-page":"801","volume":"88","author":"M Barrios","year":"2003","unstructured":"Barrios M, Jimenez-Velasco A, Roman-Gomez J, Madrigal ME, Castillejo JA, Torres A, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica. 2003;88:801\u201310.","journal-title":"Haematologica"},{"issue":"7","key":"6360_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0133671","volume":"10","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Wan L, Qin Y, Yan X, Xie K, Wang C. Donor Chimerism of B Cells and Natural Killer Cells Provides Useful Information to predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One. 2015;10(7):1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0133671.","journal-title":"PLoS One"},{"key":"6360_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bjh.13272","volume":"169","author":"C Pachon","year":"2015","unstructured":"Pachon C, Oger E, Michel G, Dalle JH, Salmon A, Nalken B, et al. Follow-up of post -transplanta minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react. Br J Haematol. 2015;169:249\u201361. https:\/\/doi.org\/10.1111\/bjh.13272.","journal-title":"Br J Haematol"},{"key":"6360_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/176526","volume":"2015","author":"Emmanuel Levrat","year":"2015","unstructured":"Levrat E, Roosnek E, Masouridi S, Mohty B, Ansari M, Villard J, et al. Very long term stability of mixed Chimerism after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Bone Marrow Res. 2015. https:\/\/doi.org\/10.1155\/2015\/176526.","journal-title":"Bone Marrow Research"},{"key":"6360_CR22","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/sj.leu.2403692","volume":"19","author":"A Lassaletta","year":"2005","unstructured":"Lassaletta A, Ramirez M, Montero JM, et al. Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. Bone Marrow Transplant. 2005;19:504\u20136. https:\/\/doi.org\/10.1038\/sj.leu.2403692.","journal-title":"Bone Marrow Transplant"},{"key":"6360_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jcma.2018.06.005","volume":"81","author":"CT Chen","year":"2018","unstructured":"Chen CT, Gau JP, Liu JH, Chiou TJ, Hsiao LT, Liu YC. Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia. J Chin Med Assoc. 2018;81:1038\u201343. https:\/\/doi.org\/10.1016\/j.jcma.2018.06.005.","journal-title":"J Chin Med Assoc"},{"key":"6360_CR24","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.bbmt.2017.12.801","volume":"24","author":"M Faraci","year":"2018","unstructured":"Faraci M, Bognasco F, Leoni M, Giardino S, Terranova P, Subissi L, Di Duca M, Di Martino D, Lanino E. Evaluation of chimerism dynamics after allogeneic hematopoietic stem cell transplantation in children with nonmalignant diseases. Biol Blood Marrow Transplant. 2018;24:1088\u2013102. https:\/\/doi.org\/10.1016\/j.bbmt.2017.12.801.","journal-title":"Biol Blood Marrow Transplant"},{"key":"6360_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.clml 2017.06.008","volume":"17","author":"I Sakellarii","year":"2017","unstructured":"Sakellarii I, Batsis I, Bousiou Z, Mallouri D, Constantinou V, Gavriilaki E, et al. The role of low-dose anti-thymocyte globulin as standard prophylaxis in mismatched and matched unrelated hematopoietic peripheral stem cell transplantation for hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2017;17:658\u201366. https:\/\/doi.org\/10.1016\/j.clml2017.06.008.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6360_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.bbmt.2008.12.496","volume":"15","author":"G Mossallam","year":"2009","unstructured":"Mossallam G, Kamel AM, Storer B, Martin PJ. Prognostic utility of routine Chimerism testing at 2-6 months after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:352\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"6360_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/bmt.2008.155","volume":"42","author":"KC Doney","year":"2008","unstructured":"Doney KC, Loken MR, Bryant EM, et al. Lack of utility of chimerism studies obtained 2\u20133 months after myeloablative hematopoietic cell transplantation for ALL. Bone Marrow Transplant. 2008;42:271\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"6360_CR28","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1399-0012.2005.00345.x","volume":"19","author":"M Jaksch","year":"2005","unstructured":"Jaksch M, Uzunel M, Remberger M, Sundberg B, Mattsson J. Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV. Clin Transpl. 2005;19:346\u20139. https:\/\/doi.org\/10.1111\/j.1399-0012.2005.00345.x.","journal-title":"Clin Transpl"},{"key":"6360_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pbc.26464","volume":"64","author":"B Horn","year":"2017","unstructured":"Horn B, Wahlstrom JT, Melton A, Liou A, Ouachee-Chardin M, Sunkersett G, et al. Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia. Pediatr Blood Cancer. 2017;64:1\u20135. https:\/\/doi.org\/10.1002\/pbc.26464.","journal-title":"Pediatr Blood Cancer"},{"key":"6360_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2016.10.006","volume":"23","author":"E Rettinger","year":"2017","unstructured":"Rettinger E, Merker M, Salzmann-Manrique E, Kreyenberg H, Krenn T, D\u00fcrken M, et al. Pre-Emptive immunotherapy for clearance of molecular disease in childhood acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant. 2017;23:87\u201395. https:\/\/doi.org\/10.1016\/j.bbmt.2016.10.006.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6360-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6360-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T19:26:57Z","timestamp":1606246017000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6360-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6360"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6360-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13465\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13465\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.13465\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"11 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the Medical University of Lublin (KE-0254\/70\/2010).All of participants have written consent to participate and publish the data. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individuals included in the study and their parents or guardians on behalf of any participant under the age of 16.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1141"}}